Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics SVP of Finance Joseph R. Young reported an open-market sale of 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The shares were sold solely to cover tax withholding on vesting RSUs under a mandated sell-to-cover arrangement and were not a discretionary trade. After this transaction, Young directly held 64,722 shares.
Vera Therapeutics, Inc. chief financial officer Sean Grant reported an open‑market sale of 4,949 shares of Class A common stock at a weighted‑average price of $41.9839 per share. According to the disclosure, the transaction was a mandated sell‑to‑cover trade to satisfy tax withholding obligations from vesting restricted stock units rather than a discretionary sale.
After this transaction, Grant directly held 114,181 Vera Therapeutics shares and indirectly held 5,000 additional shares through a trust. The sale occurred as part of trading orders executed over two business days beginning on February 23, 2026 and ending on February 24, 2026.
Vera Therapeutics president and CEO Marshall Fordyce reported a mandated sale of 16,925 shares of Class A common stock. The shares were sold in open-market "sell-to-cover" transactions solely to satisfy tax withholding obligations tied to vesting restricted stock units.
The weighted-average sale price was $41.9839 per share, with individual trades executed between $41.005 and $42.84 over two business days beginning on February 23, 2026. After these sales, Fordyce directly holds 257,163 shares, with additional indirect holdings of 122,949 shares held by a GRAT and 99,081 shares held by a trust.
Vera Therapeutics Chief Operating Officer David Lee Johnson reported an open-market sale of 2,579 shares of Class A common stock at a weighted-average price of $41.9839 per share. After this transaction, he directly owned 45,727 shares.
According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The sale was mandated by the company’s sell-to-cover election and is described as not a discretionary trade by the executive.
Vera Therapeutics, Inc. Chief Regulatory Officer William D. Turner reported an open-market sale of 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans and did not represent a discretionary trade by Turner. The trades to satisfy withholding occurred over two business days, from February 23 to February 24, 2026. After these transactions, Turner beneficially owned 45,313 shares of Class A common stock.
Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported an open-market sale of 1,582 shares of Class A common stock. The shares were sold on February 23, 2026 at a weighted-average price of 41.9839 per share to satisfy tax withholding obligations from vesting restricted stock units.
The sale was executed under the company’s equity incentive plans as a mandated “sell-to-cover” transaction and was not a discretionary trade by Skelton. After this sale, he beneficially owned 64,218 shares of Vera Therapeutics Class A common stock.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 1,800 common shares of VERA.
The filing lists the shares as restricted stock vesting under a registered plan with a vesting/transaction date of 02/20/2026 and a filing/receipt date of 02/23/2026. The securities are listed on NASDAQ.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 2,600 shares of common stock of VERA (listed on NASDAQ). The sale is tied to restricted stock vesting under a registered plan with an effective date of 02/20/2026.
VERA submitted a Form 144 notice for a proposed sale of 5,700 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/20/2026. The filing appears on or about 02/23/2026 and references NASDAQ.
Morgan Stanley Smith Barney LLC reported the sale of 2,500 restricted common shares under a registered plan, with the transaction dated 02/20/2026 and the Form 144 filed on 02/23/2026. The filing lists an aggregate amount of $105,087.50 and identifies the exchange as NASDAQ.